Absci Collaborates with AMD for $20 Million AI Drug Discovery Partnership

Absci Corporation has entered a strategic partnership with AMD, which includes a $20 million investment to enhance AI capabilities in drug discovery. The collaboration will focus on utilizing AMD's Instinct accelerators and ROCm software to improve Absci's de novo antibody design efforts. This endeavor reflects the increasing demand for AI applications in the pharmaceutical industry, aiming at delivering better biologics in a more efficient manner. The agreement involves Absci transferring its AI development tasks to AMD GPUs, contingent on performance and cost criteria, as per their memorandum of understanding. Absci, noted for its data-centric generative AI drug creation platform, combines AI with laboratory technologies to optimize drug characteristics essential for expedited clinical success. Based in Vancouver, Washington, with research facilities in New York and Switzerland, Absci empowers the AI drug creation process through advanced technologies and strategic partnerships.